Theophylline
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Theophylline: From Asthma/COPD (Bronchodilator) to Thrombotic Disease
One-Sentence Summary
Theophylline is classically used as a bronchodilator/anti-inflammatory agent for asthma and COPD via non-selective phosphodiesterase (PDE) inhibition and adenosine receptor antagonism (original indication and detailed MOA are not recorded in this evidence pack — Data Gaps DG001/DG002). The TxGNN model's top-ranked prediction for this drug is Thrombotic Disease, but this direction is currently supported by 0 clinical trials and 19 publications, none of which directly test theophylline's antithrombotic effect. This is a high-score, low-evidence model prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no NZ license data); classically a bronchodilator for asthma/COPD |
| Predicted New Indication | Thrombotic Disease |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on known pharmacology, theophylline is a methylxanthine that acts as a non-selective phosphodiesterase (PDE) inhibitor and adenosine receptor antagonist, raising intracellular cAMP — a mechanism established for airway smooth-muscle relaxation and anti-inflammatory effects in obstructive lung disease.
The link between this known respiratory mechanism and the model's top-ranked prediction of "Thrombotic Disease" is not well established. cAMP elevation is a pathway shared with some antiplatelet mechanisms (e.g., adenosine/milrinone-mediated platelet inhibition), which offers a theoretical rationale for exploring antiplatelet activity. However, the 19 literature results returned for this pairing are largely indirect: platelet/neutrophil activation biomarker studies, pharmacokinetics of an unrelated antiplatelet drug (ticlopidine), microRNA quantification methodology, and blood-sample-processing papers in which theophylline appears only as an anticoagulant additive rather than a therapeutic agent under study.
In short, this is a high TxGNN confidence score without corroborating direct clinical or mechanistic evidence — a pattern that warrants a Hold rather than active pursuit at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8055680 | 1994 | Review | Clinical Pharmacokinetics | Review of antiplatelet agent ticlopidine; does not study theophylline |
| 6771102 | 1980 | Review | CRC Crit Rev Biochem | Background review of prostaglandin/thromboxane pathways in platelet aggregation and atherosclerosis |
| 749930 | 1978 | Other | Br J Haematol | Radioimmunoassay for platelet factor 4; theophylline used only as an anticoagulant additive in sample prep |
| 21719422 | 2011 | Cohort | Rheumatology (Oxford) | Platelet/neutrophil activation studied in Behçet's disease; no theophylline intervention |
| 15475744 | 2004 | Other | Inflamm Bowel Dis | Platelet-leukocyte aggregate formation in IBD; not a theophylline study |
| 29956444 | 2018 | Other | J Thromb Haemost | Endothelial Weibel-Palade body exocytosis and hemostasis mechanisms; no theophylline data |
| 8981060 | 1996 | Other | Gen Pharmacol | cAMP-mediated platelet inhibition by milrinone/adenosine — mechanistically adjacent pathway, not theophylline itself |
| 26764324 | 2016 | Other | J Nutrition | Aged garlic extract inhibits platelet aggregation via cAMP/cGMP signaling; theophylline not tested |
| 6241135 | 1984 | Other | Cor et Vasa | T-lymphocyte subset study in vascular disease using "theophylline-resistant" cell classification (assay term, not therapeutic use) |
| 14231672 | 1964 | Other | Z Gesamte Inn Med | Historical case discussion of chronic cor pulmonale from thromboembolic disease; no theophylline data (abstract unavailable) |
Overall, none of the 19 returned publications directly evaluate theophylline's efficacy in thrombotic disease — most are background platelet-biology, methodology, or unrelated-drug studies.
New Zealand Market Information
Theophylline currently holds no New Zealand market authorization (0 licenses on record in this evidence pack).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score (99.62%) is high, but there are zero clinical trials and no literature directly demonstrating an antithrombotic effect for theophylline — the supporting publications are indirect background studies. This does not meet the bar to progress past model-prediction-only status (L5).
To proceed, the following is needed:
- TFDA/Medsafe package insert data — warnings and contraindications (DG001, Blocking)
- Detailed mechanism of action data from DrugBank (DG002, High)
- Targeted preclinical or mechanistic studies on theophylline's effect on platelet function/coagulation
- Drug interaction (DDI) data, currently not found
Note: Within this same evidence pack, two other TxGNN-predicted indications for theophylline have materially stronger support and may warrant separate evaluation — Obstructive Lung Disease (L2, Proceed with Guardrails; multiple cohort studies/reviews consistent with theophylline's known bronchodilator/anti-inflammatory mechanism) and Nasal Cavity Disease (L2; a completed Phase 2 RCT of nasal theophylline irrigation for post-viral olfactory dysfunction, n=27).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.